Investor Relations

Company Overview

KaloBios Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML.

Latest Financial Results

Q1 2017

Quarter Ended Mar 31, 2017

Latest 10-K

For Fiscal Year 2016

Download 10-K

Stock Information






52 week Low/High

Day Low/High

Contact Information

Investor Relations

MZ Group
Mike Cole
T: 949-259-4988

Transfer Agent

Computershare Inc.
211 Quality Circle
Suite 210
College Station, TX 77845
T: 877-873-6374